Salud financiera de hoja de balance de BrainCool

Salud financiera controles de criterios 4/6

BrainCool tiene un patrimonio de los accionistas total de SEK153.8M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK167.6M y SEK13.7M respectivamente.

Información clave

Ratio deuda-patrimonio

SEK 0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	SEK 41.27m
Patrimonio	SEK 153.83m
Total pasivo	SEK 13.74m
Activos totales	SEK 167.56m

Actualizaciones recientes sobre salud financiera

Recent updates

Is BrainCool (NGM:BRAIN) In A Good Position To Invest In Growth?

Mar 24

Here's Why BrainCool (NGM:BRAIN) Can Afford Some Debt

Nov 17

We Think BrainCool (NGM:BRAIN) Has A Fair Chunk Of Debt

Jul 23

Is BrainCool (NGM:BRAIN) A Risky Investment?

Mar 07

How Much Did BrainCool's(NGM:BRAIN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 14

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK83.0M) de BRAIN superan a sus pasivos a corto plazo (SEK13.7M).

Pasivo a largo plazo: BRAIN no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: BRAIN está libre de deudas.

Reducción de la deuda: BRAIN no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 5.1%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: BRAIN tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: BRAIN tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 9.4% cada año

Salud financiera de hoja de balance de BrainCool

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Is BrainCool (NGM:BRAIN) In A Good Position To Invest In Growth?

Here's Why BrainCool (NGM:BRAIN) Can Afford Some Debt

We Think BrainCool (NGM:BRAIN) Has A Fair Chunk Of Debt

Is BrainCool (NGM:BRAIN) A Risky Investment?

Recent updates

Third quarter 2024 earnings released

Second quarter 2024 earnings released

Braincool AB (Publ) Approves Board Appointments

BrainCool AB (publ) Announces Roger Henriksson Declines Re-Election as Board Member

BrainCool AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 85.763172 million.

BrainCool AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 85.763172 million.

BrainCool AB (publ) to Report Fiscal Year 2024 Results on Feb 10, 2025

Full year 2023 earnings released

Braincool AB (Publ) Announces Karolinska Starts the Clinical Study PRINCESS 2 with BrainCool's Product RhinoChill® System

New major risk - Share price stability

BrainCool AB (publ) and University of Freiburg Announces Start of Pivotal Clinical Trial (Cottis 2) for Combined Target Temperature Management and Thrombectomy After Ischemic Stroke

CEO & Director recently sold kr254k worth of stock

Third quarter 2023 earnings released

Braincool AB (Publ) Announces New Clinical Study Evaluating Early Hypothermia Treatment After Cardiac Arrest with the Braincool System and Rhinochill System

CEO & Director recently bought kr53k worth of stock

American Medical Association Approves New Current Procedural Terminology Code for Cryotherapy Using BrainCool's Cooral System

BrainCool AB (publ) Announces New CPT Code from AMA for Cooral® System supports Pathway to Reimbursement in the U.S

CEO & Director recently bought kr62k worth of stock

Second quarter 2023 earnings released

New major risk - Share price stability

Braincool AB (Publ) Introduces Minichill in Japan

Braincool AB (Publ) Announces New Patent Application for Rhinochill Technology Paves the Way for New Possibilities

BrainCool AB (publ) Receives Patent Approval for "Shivering" in the EU for the Product BrainCool System

Braincool AB (Publ) Announces International Clinical Study with Rhinochill®System of Patients with Sudden Cardiac Arrest Obtain Ethical Approval

First quarter 2023 earnings released

BrainCool AB (publ) to Report Q3, 2023 Results on Nov 30, 2023

BraincCool Launches New Commercialization Strategy for Its Breakthrough Product Cooral ®System Aiming for Reimbursement in the U.S

Is BrainCool (NGM:BRAIN) In A Good Position To Invest In Growth?

BrainCool AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

Third quarter 2022 earnings released: kr0.17 loss per share (vs kr0.12 loss in 3Q 2021)

Here's Why BrainCool (NGM:BRAIN) Can Afford Some Debt

No independent directors

BrainCool AB (publ) to Report Q3, 2022 Results on Nov 30, 2022

BrainCool AB (publ) Announces FDA approval of Cooral

Second quarter 2022 earnings released: kr0.18 loss per share (vs kr0.13 loss in 2Q 2021)

We Think BrainCool (NGM:BRAIN) Has A Fair Chunk Of Debt

First quarter 2022 earnings released: kr0.14 loss per share (vs kr0.12 loss in 1Q 2021)

BrainCool AB (publ) to Report Q1, 2022 Results on May 31, 2022

No independent directors

CEO & Director recently bought kr73k worth of stock

CEO & Director recently bought kr195k worth of stock

CEO & Director recently bought kr195k worth of stock

CEO & Director recently bought kr195k worth of stock

Is BrainCool (NGM:BRAIN) A Risky Investment?

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 2Q 2020)

CEO & Director recently bought kr238k worth of stock

BrainCool AB (publ), Annual General Meeting, Apr 15, 2021

Full year 2020 earnings released: kr0.68 loss per share (vs kr1.43 loss in FY 2019)

BrainCool AB (publ) Receives FDA "Breakthrough Device" Designation for Cooral® System for Prevention of Oral Mucositis

New 90-day high: kr9.17

How Much Did BrainCool's(NGM:BRAIN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Third quarter 2020 earnings released: kr0.12 loss per share

New 90-day low: kr7.00

Braincool AB Announces Statistically Significant Late-Breaking Clinical Data At SMO Virtual Congress 2020

New 90-day high - kr11.24

BrainCool AB (publ) to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr7.15

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera